Company / Accounts Receivable
CUMBERLAND PHARMACEUTICALS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$16.9M
FY2025
5-year range
$6.9M / $16.9M
FY2021-FY2025
Trend
+44.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $7M in FY2021 to $17M in FY2025.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of +6.5%.
Improved from $10M to $17M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.8%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 44.8% year-over-year.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.9M | +44.8% |
| FY2024 | $11.7M | +19.9% |
| FY2023 | $9.8M | -25.9% |
| FY2022 | $13.2M | +91.4% |
| FY2021 | $6.9M | -44.4% |
| FY2020 | $12.4M | +57.5% |
| FY2019 | $7.9M | +0.2% |
| FY2018 | $7.8M | -6.6% |
| FY2017 | $8.4M | +14.5% |
| FY2016 | $7.3M | +20.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026